341 related articles for article (PubMed ID: 23580590)
21. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
[TBL] [Abstract][Full Text] [Related]
22. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
Ding Z; Wu CJ; Chu GC; Xiao Y; Ho D; Zhang J; Perry SR; Labrot ES; Wu X; Lis R; Hoshida Y; Hiller D; Hu B; Jiang S; Zheng H; Stegh AH; Scott KL; Signoretti S; Bardeesy N; Wang YA; Hill DE; Golub TR; Stampfer MJ; Wong WH; Loda M; Mucci L; Chin L; DePinho RA
Nature; 2011 Feb; 470(7333):269-73. PubMed ID: 21289624
[TBL] [Abstract][Full Text] [Related]
23. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R
Cancer Res; 2008 Aug; 68(16):6822-30. PubMed ID: 18701508
[TBL] [Abstract][Full Text] [Related]
24. Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer.
Corbin JM; Overcash RF; Wren JD; Coburn A; Tipton GJ; Ezzell JA; McNaughton KK; Fung KM; Kosanke SD; Ruiz-Echevarria MJ
Prostate; 2016 Jan; 76(1):97-113. PubMed ID: 26417683
[TBL] [Abstract][Full Text] [Related]
25. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
Cai C; Wang H; Xu Y; Chen S; Balk SP
Cancer Res; 2009 Aug; 69(15):6027-32. PubMed ID: 19584279
[TBL] [Abstract][Full Text] [Related]
26. Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.
Barquilha CN; Santos NJ; Monção CCD; Barbosa IC; Lima FO; Justulin LA; Pértega-Gomes N; Felisbino SL
Oxid Med Cell Longev; 2020; 2020():2148562. PubMed ID: 32411320
[TBL] [Abstract][Full Text] [Related]
27. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract][Full Text] [Related]
28. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
[TBL] [Abstract][Full Text] [Related]
29. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.
Shappell SB; Olson SJ; Hannah SE; Manning S; Roberts RL; Masumori N; Jisaka M; Boeglin WE; Vader V; Dave DS; Shook MF; Thomas TZ; Funk CD; Brash AR; Matusik RJ
Cancer Res; 2003 May; 63(9):2256-67. PubMed ID: 12727848
[TBL] [Abstract][Full Text] [Related]
30. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
Linn DE; Bronson RT; Li Z
PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
[TBL] [Abstract][Full Text] [Related]
31. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
32. Protocols for Studies on TMPRSS2/ERG in Prostate Cancer.
Pakula H; Linn DE; Schmidt DR; Van Gorsel M; Vander Heiden MG; Li Z
Methods Mol Biol; 2018; 1786():131-151. PubMed ID: 29786791
[TBL] [Abstract][Full Text] [Related]
33. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
[TBL] [Abstract][Full Text] [Related]
34. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
[TBL] [Abstract][Full Text] [Related]
35. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.
Liao CP; Lin TP; Li PC; Geary LA; Chen K; Vaikari VP; Wu JB; Lin CH; Gross ME; Shih JC
Oncogene; 2018 Sep; 37(38):5175-5190. PubMed ID: 29844571
[TBL] [Abstract][Full Text] [Related]
36. TIP5 primes prostate luminal cells for the oncogenic transformation mediated by
Pietrzak K; Kuzyakiv R; Simon R; Bolis M; Bär D; Aprigliano R; Theurillat JP; Sauter G; Santoro R
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3637-3647. PubMed ID: 32024754
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.
Liao Y; Guo Z; Xia X; Liu Y; Huang C; Jiang L; Wang X; Liu J; Huang H
J Exp Clin Cancer Res; 2019 Apr; 38(1):157. PubMed ID: 30975171
[TBL] [Abstract][Full Text] [Related]
39. TMPRSS2-ERG fusion promotes prostate cancer metastases in bone.
Deplus R; Delliaux C; Marchand N; Flourens A; Vanpouille N; Leroy X; de Launoit Y; Duterque-Coquillaud M
Oncotarget; 2017 Feb; 8(7):11827-11840. PubMed ID: 28055969
[TBL] [Abstract][Full Text] [Related]
40. New insights into prostate cancer stem cells.
Chen X; Rycaj K; Liu X; Tang DG
Cell Cycle; 2013 Feb; 12(4):579-86. PubMed ID: 23370446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
